Intravenous Pegloticase Market Analysis

Age Group (Pediatric, Adult, Geriatric)

In terms of age group, the adult segment is is anticipated to hold 45% share of the global intravenous pegloticase market by 2036. The segment growth can be attributed to the increasing presence of gout disease in the adult population. According to research, the global gout prevalent cases in individuals aged 15-39 years was 5.21 million in 2019 with the annual occurrence gradually increasing from 38.71 to 46 per 100,000 population from 1990 to 2019. The higher prevalence of gout in adults can be credited to the level of estrogen in their body and consumption of diet such as red meat and alcohol which are responsible for the regulation of uric acid that causes gout.

End Users (Hospital Pharmacies, Retail Pharmacies & Others)

The hospital pharmacies segment in the intravenous pegloticase market is estimated to gain a significant share of about 46% in the year 2036. The segment growth can be attributed to the high frequency of patients in the hospitals. As patients seek medical care and treatment from the hospital, the demand for pharmaceutical services within the healthcare faculties has surged as a result almost every hospital has its pharmacy. Hospital pharmacies play a crucial role in ensuring patients receive the medications they need promptly and safely during their stay.

Our in-depth analysis of the global market includes the following segments: